Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Share-based Compensation (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Share-based Compensation for 5 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Share-based Compensation rose 29.77% to $1.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.3 million, a 37.74% increase, with the full-year FY2024 number at $5.3 million, up 37.74% from a year prior.
  • Share-based Compensation was $1.2 million for Q4 2024 at Actinium Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q1 2024 to a low of -$1.2 million in Q4 2021.
  • A 4-year average of $746562.5 and a median of $948500.0 in 2022 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 179.59% in 2022; the steepest drop was 7.41% in 2022.
  • Actinium Pharmaceuticals' Share-based Compensation stood at -$1.2 million in 2021, then surged by 179.59% to $979000.0 in 2022, then fell by 5.31% to $927000.0 in 2023, then increased by 29.77% to $1.2 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Share-based Compensation are $1.2 million (Q4 2024), $1.3 million (Q3 2024), and $1.4 million (Q2 2024).